Literature DB >> 2059965

Comparison of transforming growth factor beta and a human tumour-derived suppressor factor.

S S Somers1, J F Dye, P J Guillou.   

Abstract

Serum-free supernatants from the human melanoma cell line G361 contain a factor that can potently suppress the generation of tumouricidal lymphokine-activated killer (LAK) cells in response to interleukin-2. To characterise the suppressive factor of tumour origin we performed a number of physicochemical and functional comparisons with another immunosuppressive protein, transforming growth factor beta (TGF beta). The bioactivity of tumour-derived suppressor factor (TDSF), assayed by suppression of LAK cell generation, was unaffected by a reducing agent but lost when denatured with a chaotropic agent. In contrast, TGF beta was inactivated by reduction but not denaturation. TDSF lost bioactivity in conditions of pH less than 4, whereas TGF beta showed no loss of activity. The TDSF moiety has an estimated pI of 4.3 and a molecular mass of 69-87 kDa. This differs from published values of pI 9.5, and 25 kDa molecular mass for TGF beta. Anti-TGF beta antiserum reversed the effects of TGF beta but did not affect the suppression of LAK cell generation caused by TDSF. These findings provide compelling evidence that the TDSF moiety is not TGF beta, and may be a novel immunoregulatory cytokine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2059965     DOI: 10.1007/bf01744940

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  27 in total

1.  Simplified quantitation of cytotoxicity by integration of specific lysis against effector cell concentration at a constant target cell concentration and measuring the area under the curve.

Authors:  J F Dye; S S Somers; P J Guillou
Journal:  J Immunol Methods       Date:  1991-04-08       Impact factor: 2.303

2.  Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.

Authors:  S A Rosenberg; M T Lotze; J C Yang; P M Aebersold; W M Linehan; C A Seipp; D E White
Journal:  Ann Surg       Date:  1989-10       Impact factor: 12.969

3.  Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro.

Authors:  P J Guillou; P C Sedman; C W Ramsden
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Immunoregulatory factors derived from human tumors. II. Partial purification and further immunobiochemical characterization of a human sarcoma-derived immunosuppressive factor expressing HLA-DR and immunoglobulin-related determinants.

Authors:  J A Roth; B A Osborne; R S Ames
Journal:  J Immunol       Date:  1983-01       Impact factor: 5.422

5.  Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells.

Authors:  J J Mulé; S L Schwarz; A B Roberts; M B Sporn; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

6.  Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness.

Authors:  A H Rook; J H Kehrl; L M Wakefield; A B Roberts; M B Sporn; D B Burlington; H C Lane; A S Fauci
Journal:  J Immunol       Date:  1986-05-15       Impact factor: 5.422

7.  A new type of transforming growth factor-beta, TGF-beta 3.

Authors:  R Derynck; P B Lindquist; A Lee; D Wen; J Tamm; J L Graycar; L Rhee; A J Mason; D A Miller; R J Coffey
Journal:  EMBO J       Date:  1988-12-01       Impact factor: 11.598

8.  Suppression of the generation of lymphokine-activated killer (LAK) cells by serum-free supernatants of in vitro maintained tumour cell lines.

Authors:  P J Guillou; C W Ramsden; S S Somers; P C Sedman
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

9.  Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium.

Authors:  R M Lyons; J Keski-Oja; H L Moses
Journal:  J Cell Biol       Date:  1988-05       Impact factor: 10.539

10.  Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth.

Authors:  J H Kehrl; L M Wakefield; A B Roberts; S Jakowlew; M Alvarez-Mon; R Derynck; M B Sporn; A S Fauci
Journal:  J Exp Med       Date:  1986-05-01       Impact factor: 14.307

View more
  1 in total

1.  Expression of a suppressive p15E-related epitope in colorectal and gastric cancer.

Authors:  S Foulds; C H Wakefield; M Giles; J Gillespie; J F Dye; P J Guillou
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.